|
|
||||||||||
|
J Am Coll Cardiol, 2000; 36:288-293 © 2000 by the American College of Cardiology Foundation |
a Laboratory of Experimental and Clinical Interventional Cardiology, University Federico II, Naples, Italy
* Department of Molecular and Clinical Endocrinology and Oncology, University Federico II, Naples, Italy
Manuscript received January 28, 1999; revised manuscript received January 17, 2000, accepted March 2, 2000.
Reprint requests and correspondence: Dr. Ciro Indolfi, Division of Cardiology, University Federico II, Via Pansini, 5, 80131 Napoli, Italy
Indolfi{at}unina.it
OBJECTIVES
The aims of the present study were to assess 1) the effect of 8-Cl-cAMP (cyclic-3'-5'-adenosine monophosphate) on vascular smooth muscle cell (VSMC) proliferation in vitro and 2) the efficacy of systemic administration of 8-Cl-cAMP on neointimal formation after balloon injury in vivo.
BACKGROUND
Neointimal formation after vascular injury is responsible for restenosis after arterial stenting. Recently, 8-Cl-cAMP, a cAMP analogue that induces growth arrest, has been safely administered in phase I studies in humans.
METHODS
The effect of 8-Cl-cAMP on cell proliferation was first assessed on SMCs in vitro. To study the effects of cAMP in vivo, balloon injury was performed in 67 rats using a 2F Fogarty balloon catheter.
RESULTS
The 8-Cl-cAMP markedly inhibited VSMC proliferation in vitro, reduced protein kinase A (PKA) RI
subunit expression, and induced PKA RIIß subunit expression. In addition, 8-Cl-cAMP reduced, in a dose-dependent manner, neointimal area and neointima/media ratio after balloon injury. The proliferative activity, assessed by proliferating nuclear cell antigen immunostaining, revealed a reduction of proliferative activity of VSMCs in vivo in the 8-Cl-cAMP group. Moreover, the systemic administration of 8-Cl-cAMP did not affect renal function, blood pressure and heart rate.
CONCLUSIONS
We conclude that 8-Cl-cAMP potently inhibits VSMC proliferation in vitro and reduces neointima formation by balloon injury in vivo after systemic administration. These data may have a clinical relevance in designing future strategies to prevent restenosis after arterial stenting and perhaps after percutaneous transluminal coronary angioplasty.
| ||||||||||||||||||||||
This article has been cited by other articles:
![]() |
D. G. Tilley and D. H. Maurice Vascular Smooth Muscle Cell Phenotype-Dependent Phosphodiesterase 4D Short Form Expression: Role of Differential Histone Acetylation on cAMP-Regulated Function Mol. Pharmacol., September 1, 2005; 68(3): 596 - 605. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-J. Kim, K.-G. Park, K.-M. Lee, H.-S. Kim, S.-Y. Kim, C.-S. Kim, S.-L. Lee, Y.-C. Chang, J.-Y. Park, K.-U. Lee, et al. Cilostazol Inhibits Vascular Smooth Muscle Cell Growth by Downregulation of the Transcription Factor E2F Hypertension, April 1, 2005; 45(4): 552 - 556. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Sakaguchi, T. Asai, D. Belov, M. Okada, D. J. Pinsky, A. M. Schmidt, and Y. Naka Influence of ischemic injury on vein graft remodeling: Role of cyclic adenosine monophosphate second messenger pathway in enhanced vein graft preservation J. Thorac. Cardiovasc. Surg., January 1, 2005; 129(1): 129 - 137. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Torella, D. Leosco, C. Indolfi, A. Curcio, C. Coppola, G. M. Ellison, V. G. Russo, M. Torella, G. L. Volti, F. Rengo, et al. Aging exacerbates negative remodeling and impairs endothelial regeneration after balloon injury Am J Physiol Heart Circ Physiol, December 1, 2004; 287(6): H2850 - H2860. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. A. Tallant and M. A. Clark Molecular Mechanisms of Inhibition of Vascular Growth by Angiotensin-(1-7) Hypertension, October 1, 2003; 42(4): 574 - 579. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Indolfi, D. Torella, C. Coppola, A. Curcio, F. Rodriguez, A. Bilancio, A. Leccia, O. Arcucci, M. Falco, D. Leosco, et al. Physical Training Increases eNOS Vascular Expression and Activity and Reduces Restenosis After Balloon Angioplasty or Arterial Stenting in Rats Circ. Res., December 13, 2002; 91(12): 1190 - 1197. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Indolfi Genetic factors in atherosclerosis: status and perspectives Eur. Heart J. Suppl., March 1, 2002; 4(suppl_B): B14 - B16. [Abstract] [PDF] |
||||
![]() |
S. D. Rybalkin, I. Rybalkina, J. A. Beavo, and K. E. Bornfeldt Cyclic Nucleotide Phosphodiesterase 1C Promotes Human Arterial Smooth Muscle Cell Proliferation Circ. Res., February 8, 2002; 90(2): 151 - 157. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Ii, M. Hoshiga, R. Fukui, N. Negoro, T. Nakakoji, F. Nishiguchi, E. Kohbayashi, T. Ishihara, and T. Hanafusa Beraprost sodium regulates cell cycle in vascular smooth muscle cells through cAMP signaling by preventing down-regulation of p27Kip1 Cardiovasc Res, December 1, 2001; 52(3): 500 - 508. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. B. Jourdan, N. A. Mason, L. Long, P. G. Philips, M. R. Wilkins, and N. W. Morrell Characterization of adenylyl cyclase isoforms in rat peripheral pulmonary arteries Am J Physiol Lung Cell Mol Physiol, June 1, 2001; 280(6): L1359 - L1369. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. T. Wong, L. P. Baker, K. Trinh, M. Hetman, L. A. Suzuki, D. R. Storm, and K. E. Bornfeldt Adenylyl Cyclase 3 Mediates Prostaglandin E2-induced Growth Inhibition in Arterial Smooth Muscle Cells J. Biol. Chem., August 31, 2001; 276(36): 34206 - 34212. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. D. Rybalkin, I. Rybalkina, J. A. Beavo, and K. E. Bornfeldt Cyclic Nucleotide Phosphodiesterase 1C Promotes Human Arterial Smooth Muscle Cell Proliferation Circ. Res., February 8, 2002; 90(2): 151 - 157. [Abstract] [Full Text] [PDF] |
||||
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |